Absci Corporation (ABSI)
$
3.01
+0.08 (2.66%)
Key metrics
Financial statements
Free cash flow per share
-0.5441
Market cap
452.6 Million
Price to sales ratio
210.5201
Debt to equity
0.0296
Current ratio
5.8905
Income quality
0.7042
Average inventory
0
ROE
-0.6049
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Absci Corporation, a drug and target discovery company founded in 2011 and headquartered in Vancouver, Washington, provides biologic drug candidates and production cell lines for partners in the United States using its integrated drug creation platform. This platform unifies the processes of drug discovery and cell line development, allowing for the efficient creation of biologics. The company recorded an operating income of $0.00 reflecting its earnings from core operations. Furthermore, with a weighted average number of diluted shares outstanding at 136,776,885.00 the company illustrates potential dilution effects. Absci reported an income before tax of -$115,114,000.00 showcasing its pre-tax profitability while earning an interest income of $0.00 highlighting the effectiveness of its financial investments. The company achieved a revenue of $0.00 indicating its niche market focus and commitment to advancing drug development. In the financial landscape, Absci’s stock is affordable at $2.61 making it suitable for budget-conscious investors. The stock has a high average trading volume of 3,421,852.00 indicating strong liquidity, which can attract a diverse range of investors. With a market capitalization of $452,618,308.00 the company is classified as a small-cap player, positioning it as a dynamic entity within the biotechnology sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with innovative solutions. Additionally, Absci belongs to the Healthcare sector, driving innovation and growth, and emphasizing its pivotal role in shaping the future of drug discovery and development.
Is Absci Corporation (ABSI) a good investment?
Investing in Absci Corporation (ABSI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Absci Corporation (ABSI)'s stock forecast?
Analysts predict Absci Corporation stock to fluctuate between $2.01 (low) and $5.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Absci Corporation's market capitalization?
As of 2026-03-25, Absci Corporation's market cap is $452,618,308, based on 150,371,531 outstanding shares.
How does Absci Corporation compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Absci Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Absci Corporation (ABSI) stock?
To buy Absci Corporation (ABSI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABSI. Place an order (Market, Limit, etc.).
What is the best time to invest in Absci Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Absci Corporation perform in the last earnings report?
Revenue: $0 | EPS: -$0.84 | Growth: -10.64%.
Where can I find Absci Corporation's investor relations reports?
Visit https://www.absci.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Absci Corporation?
You can explore historical data from here
What is the all-time high and low for Absci Corporation stock?
All-time high: $28.28 (2021-08-09) | All-time low: $1.11 (2023-10-26).
What are the key trends affecting Absci Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Absci Corporation is downgraded to Hold due to a lack of differentiation for ABS-101 and a strategic pivot to ABS-201. ABS-101 failed to outperform 2nd-generation TL1A candidates, leading to halted internal development and a search for external partnerships. Focus shifts to ABS-201 for androgenetic alopecia, but meaningful efficacy data won't arrive until late 2026 or early 2027.
seekingalpha.com
Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript
zacks.com
Absci Corporation (ABSI) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.25 per share a year ago.
seekingalpha.com
Absci Corporation (ABSI) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
globenewswire.com
VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Absci's Chief Medical Officer. The inducement grant was previously approved by the Compensation Committee of Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
seekingalpha.com
Absci Corporation (ABSI) Presents at TD Cowen 46th Annual Health Care Conference Transcript
seekingalpha.com
Absci Corporation (ABSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
seekingalpha.com
Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript
zacks.com
Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
fool.com
Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already priced in the boom.
See all news
